Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's
Biotech
BioVie cuts 'most de-risked program,' will seek partner
BioVie is seeking partners for its “most de-risked program,” a phase 3-ready investigational infusion for patients with refractory ascites.
Gabrielle Masson
Mar 11, 2024 11:12am
Biogen's future Alzheimer's pipeline forms around tau, orals
Mar 7, 2024 10:25am
Karuna 'vigorously' denies wrongdoing in shareholder lawsuit
Mar 1, 2024 10:54am
Roche’s Genentech returns Alzheimer’s assets to AC Immune
Jan 22, 2024 8:47am
Scientists reflect on Roche's Alzheimer's failure a year later
Nov 15, 2023 5:00pm
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Oct 26, 2023 8:51am